Skip to main content
Year archive

Vivesto — 2016 filings

All 76 regulatory filings released by Vivesto (VIVE) in 2016, sourced directly from the official regulator.

76 Filings
2016 Period
2016 filings (76)
Filing Released Lang
Oasmia Pharmaceutical redovisar positiva resultat från studie med veckovis behandling med Apealea® (Paclical®)
Regulatory Filings
2016-12-21 Swedish
Oasmia Pharmaceutical Reports Positive Results from Study on Weekly Administration of Apealea® (Paclical®)
Regulatory Filings
2016-12-21 English
Oasmia Pharmaceutical AB’s Warrant Programs Fully Subscribed
Share Issue/Capital Change
2016-12-07 English
Optionsprogrammen i Oasmia Pharmaceutical AB fulltecknade
Remuneration Information
2016-12-07 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report H1 2017
2016-12-02 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report H1 2017
2016-12-02 English
Communiqué from Extraordinary General Meeting 2016
AGM Information
2016-11-22 English
Kommuniké från extra bolagsstämma 2016
AGM Information
2016-11-22 Swedish
Major Shareholding Notification 2016
Major Shareholding Notification
2016-11-11 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-11-04 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-11-02 English
Nexttobe förlänger lån till Oasmia Pharmaceutical
Capital/Financing Update
2016-11-02 Swedish
Nexttobe Extends Loan to Oasmia Pharmaceutical
Capital/Financing Update
2016-11-02 English
Oasmia Pharmaceutical Announces Change in Ownership
Major Shareholding Notification
2016-11-01 English
Ägarförändringar i Oasmia Pharmaceutical
Major Shareholding Notification
2016-11-01 Swedish
Ändring av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2016-10-31 Swedish
Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2016-10-31 English
Oasmia convenes an extraordinary general meeting on the 21 November, 2016.
AGM Information
2016-10-26 English
Oasmia kallar till extra bolagsstämma 21 november 2016
AGM Information
2016-10-26 Swedish
Oasmia issues new shares for acquiring an asset corresponding to SEK 25 million
Share Issue/Capital Change
2016-10-24 English
Oasmia genomför kvittningsemission om 25 miljoner kronor
Share Issue/Capital Change
2016-10-24 Swedish
Oasmia offentliggör placering av nya aktier
Capital/Financing Update
2016-10-22 Swedish
Oasmia announces private placement of new shares
Capital/Financing Update
2016-10-22 English
Oasmia in discussions concerning acquisition of novel cancer project
Regulatory Filings
2016-10-21 English
Oasmia i diskussioner om förvärv av cancerprojekt
M&A Activity
2016-10-21 Swedish
Kommuniké från årsstämma 2016
AGM Information
2016-09-27 Swedish
Communiqué from Oasmia’s Annual General Meeting 2016
AGM Information
2016-09-27 English
Interim / Quarterly Report 2016
Interim / Quarterly Report Q1 2016
2016-09-02 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Q1 2016
2016-09-02 English
Oasmia anställer Fredrik Gynnerstedt som Chief Financial Officer
Board/Management Information
2016-08-31 Swedish
Oasmia Pharmaceutical AB Appoints Fredrik Gynnerstedt as Chief Financial Officer
Board/Management Information
2016-08-31 English
Notice convening the Annual General Meeting of Shareholders in Oasmia Pharmaceutical AB
AGM Information
2016-08-26 English
Kallelse till årsstämma för Oasmia Pharmaceutical AB
AGM Information
2016-08-26 Swedish
Annual Report 2016
Annual Report FY 2016
2016-07-08 Swedish
Annual Report 2016
Annual Report FY 2016
2016-07-08 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-06-30 English
CORRECTION: Oasmia successfully completes a private placement of new convertible instruments in a total amount of SEK 42,000,000
Capital/Financing Update
2016-06-10 English
CORRECTION: Oasmia genomför en riktad emission av konvertibler om totalt 42 000 000 kronor
Capital/Financing Update
2016-06-10 Swedish
Annual Report 2016
Annual Report Q4 2016
2016-06-03 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report FY 2016
2016-06-03 English
Oasmia Pharmaceutical announces early publication of Annual Report
Report Publication Announcement
2016-06-03 English
Oasmia Pharmaceutical tidigarelägger datum för publicering av årsredovisning
Report Publication Announcement
2016-06-03 Swedish
Oasmia intensifierar processen att identifiera partners för marknadsföring och distribution samt nyutveckling baserad på företagets nanoteknologi XR17
Regulatory Filings
2016-05-26 Swedish
Oasmia Pharmaceutical to Identify International Partners for Marketing, Distribution and new Product Development based on the Company’s Nanotechnology XR17
M&A Activity
2016-05-26 English
Förtydligande till artikel i BioPharm Insight
Regulatory Filings
2016-05-11 Swedish
Clarification of article in BioPharm Insight
Regulatory Filings
2016-05-11 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-05-10 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-05-06 English
Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2016-04-29 English
Ändring av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2016-04-29 Swedish
Oasmia presenterar positiva överlevnadsdata från fas III-studie med Paclical/Apealea för behandling av äggstockscancer
Earnings Release FY 2016
2016-04-27 Swedish
Oasmia Pharmaceutical Announces Positive Overall Survival Results from Phase III Study of Paclical/Apealea for Treatment of Ovarian Cancer
Earnings Release FY 2016
2016-04-27 English
Oasmia successfully completes private placements of new convertible instruments and new shares in the total amount of SEK 45,5 million
Share Issue/Capital Change
2016-04-15 English
Oasmia genomför riktade nyemissioner av konvertibler och aktier om totalt 45,5 miljoner kronor
Capital/Financing Update
2016-04-15 Swedish
Oasmia rapporterar positiva resultat från klinisk studie med sin patenterade nanoteknologi XR17
Regulatory Filings
2016-04-05 Swedish
Oasmia Pharmaceutical Reports Positive Clinical Study Results for Proprietary XR17 Nanotechnology
Regulatory Filings
2016-04-05 English
Första patienten in i Oasmias kliniska studie med Docecal, en ny patenterad formulering av docetaxel
Regulatory Filings
2016-03-30 Swedish
Oasmia Pharmaceutical Announces Enrollment of First Patient in Clinical Study with Docecal, a Novel Formulation of Docetaxel
Legal Proceedings Report
2016-03-30 English
Förtydligande angående pressmeddelande om marknad för äggstockscancer
Legal Proceedings Report
2016-03-10 Swedish
Clarification regarding Press Release about Ovarian Cancer Market
Earnings Release FY 2016
2016-03-10 English
Earnings Release 2016
Earnings Release 9M 2016
2016-03-03 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Q3 2016
2016-03-03 English
Oasmia Pharmaceutical uppdaterar bolagspresentation
Report Publication Announcement
2016-02-29 Swedish
Oasmia Pharmaceutical Reissues Executive Summary
Report Publication Announcement
2016-02-29 English
Oasmia Pharmaceutical AB Provides Updates to Clinical Program Development
Regulatory Filings
2016-02-24 English
Uppdatering avseende Oasmia Pharmaceuticals kliniska utvecklingsprogram
Regulatory Filings
2016-02-24 Swedish
Oasmias har ansökt om marknadsföringstillstånd hos den Europeiska läkemedelsmyndigheten (EMA) för cancerläkemedlet Apealea® (Paclical®)
Regulatory Filings
2016-02-08 Swedish
Oasmia Has Submitted a Marketing Authorization Application to the European Medicines Agency for Its Lead Cancer Product Apealea® (Paclical®)
Regulatory Filings
2016-02-08 English
Oasmia presenterar vid två konferenser i New York
Regulatory Filings
2016-02-04 Swedish
Oasmia Pharmaceutical to Present at Upcoming Source Capital Group's 2016 Disruptive Growth & Healthcare Conference and BIO CEO & Investor Conference in New York
Regulatory Filings
2016-02-04 English
Oasmia Pharmaceutical förstärker och anpassar organisationen inför kommersiell fas
Board/Management Information
2016-02-02 Swedish
Oasmia Pharmaceutical Makes Key Hires; Strengthens Organizational Structure Entering Commercial Phase
Board/Management Information
2016-02-02 English
Oasmia Pharmaceutical AB (Nasdaq: OASM) to Ring the Nasdaq Stock Market Opening Bell on January 11
Delisting Announcement
2016-01-11 English
Oasmia Pharmaceutical AB öppnar Nasdaq-börsen i New York den 11:e januari
Regulatory Filings
2016-01-11 Swedish
Oasmia Submits Application for Market Approval of its Next Generation Anti-Cancer Drug Doxophos® in Russia
Legal Proceedings Report
2016-01-04 English
Oasmia ansöker om marknadsgodkännande för sitt nästa cancerläkemedel, Doxophos®, i Ryssland
Regulatory Filings
2016-01-04 Swedish